The new molecule, named GBR 830, is an anti-OX40 monoclonal antibody, Glenmark said in a statement, adding that OX40 is responsible for some autoimmune diseases.

The company said it has initiated studies for an investigational new drug (IND) application to be filed with the US Food and Drug Administration.